Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. 483
  6. /
  7. Immunomedics, Inc.
483
•Immunomedics, Inc.•August 6, 2018

Immunomedics, Inc. – FDA 483, Aug 6, 2018

Record Details

The FDA Form 483 details multiple deficiencies at Immunomedics Inc., a pharmaceutical manufacturer. The quality control unit lacks authority to investigate critical deviations, exemplified by a February 2018 data integrity breach involving manipulation of bioburden samples, misrepresentation of integrity test procedures, and backdating of batch records. This breach's scope, including its impact on pre-February 2018 process validation and commercial batches, remains unassessed due to attorney/client privileged interviews.

The retesting procedure for out-of-specification (OOS) results is inadequate, allowing routine retesting for initial OOS results and delayed non-conformance report initiation for microbiology samples. The raw material sampling and testing program is insufficient; specifically, a critical solution from a vendor has never been sampled, and product-contact materials used in cell culture are not tested for bioburden, leading to contamination deviations.

Inventory audit trails and raw material reconciliation procedures are lacking, with no records tracing raw material use, undocumented discarded materials, and an unsearchable Excel spreadsheet for inventory. The warehouse lacks adequate mapping, and quarantined and released items are stored side-by-side.

Environmental controls are deficient, with inadequate maintenance and monitoring of differential pressure in GMP areas, and unalarmed pressure differentials between critical rooms. The facility design is inadequate, lacking drains in rooms and a spill containment/disposal SOP. Production bioreactor materials are held in bags.

No signed Quality Agreement exists with

Company
Immunomedics, Inc.
Inspection date
August 6, 2018
Product type
Drugs
Office
Center for Drug Evaluation and Research
People
  • Reyes Cendoya-Chacon
  • Madushini N. Dharmasena
  • Rajiv R. Srivastava (Consumer Safety Officer)
  • Michael Pehl (Chief Executive Officer)
  • Yun Wu, Staff Fellow
View Company Profile

ID · 2df4dbaa-bc93-4d3f-b969-9be789235569

Violation Codes2
21 CFR 21021 CFR 211

Full citation text and observation details available on the Dashboard.

Other documents for Immunomedics, Inc.
  • 483 - 2020-03-10March 10, 2020
  • EIR - 2018-08-01August 1, 2018
  • 483 - 2018-08-01August 1, 2018
  • 483 - 2003-01-23January 23, 2003
  • 483

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Immunomedics, Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.